

PTO-1390 (Rev. 07-2005)

Approved for use through 3/31/2007. OMB 0651-0021

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL LETTER TO	ATTORNEY'S DOCKET NUMBER 29248/29					
DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A SUBMISSION UNDER 35 U.S.C. 371		U.S. ARPLICATION NO (FIXED VIDE 6027 CFR 1.5)				
INTERNATIONAL APPLICATION NO.	INTERNATIONAL FILING DATE	PRIORITY DATE CLAIMED				
PCT/BE2004/000172	2 December 2004 (02.12.2004)	2 December 2003 (02.12.2003)				
	SE OF D4 AND 5-HT2A ANTAGONIST GONISTS OR PARTIAL AGONISTS	S, INVERSE				
APPLICANT(S) FOR DO/EO/US	rik Buntinx	4				
Applicant herewith submits to the United S	tates Designated/Elected Office (DO/EC	/US) the following items and other information:				
1. This is a FIRST submission of items of	oncerning a submission under 35 U.S.C. 371					
2. This is a SECOND or SUBSEQUENT	submission of items concerning a submission	n under 35 U.S.C. 371.				
3. This is an express request to begin na (5), (6), (9) and (21) indicated below.	tional examination procedures (35 U.S.C. 37	1(f)). The submission must include items				
4. The US has been elected (Article 31).						
5. A copy of the International Application	on as filed (35 U.S.C. 371(c)(2))					
a. 🗹 is attached hereto (require	d only if not communicated by the Internation	al Bureau).				
b. 🖊 has been communicated b	y the International Bureau.					
c. is not required, as the app	lication was filed in the United States Receivi	ng Office (RO/US).				
6. An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)).						
a. is attached hereto.						
b. has been previously subm	nitted under 35 U.S.C. 154(d)(4).					
7. Amendments to the claims of the Int	ernational Application under PCT Article 19 (35 U.S.C. 371(c)(3))				
a. are attached hereto (required only if not communicated by the International Bureau).						
b. have been communicated	b. have been communicated by the International Bureau.					
c. have not been made; how	c. have not been made; however, the time limit for making such amendments has NOT expired.					
d. have not been made and	d. have not been made and will not be made.					
8. An English language translation of t	An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).					
9. An oath or declaration of the invento	An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).					
10. An English language translation of the Article 36 (35 U.S.C. 371(c)(5)).						
Items 11 to 20 below concern document(s) or information included:						
11. An Information Disclosure Statemen	An Information Disclosure Statement under 37 CFR 1.97 and 1.98.					
12. An assignment document for record	An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.					
13. A preliminary amendment.	A preliminary amendment.					
14. An Application Data Sheet under 37	An Application Data Sheet under 37 CFR 1.76.					
15. A substitute specification.	A substitute specification.					
16. A power of attorney and/or change of	A power of attorney and/or change of address letter.					
17. A computer-readable form of the sec	A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 37 CFR 1.821- 1.825.					
18. A second copy of the published Inter	A second copy of the published International Application under 35 U.S.C. 154(d)(4).					
19. A second copy of the English langua	A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4).					

This collection of information is required by 37 CFR 1.414 and 1.491-1.492. The information is required to obtain or retain a benefit by the public, which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 15 minutes to complete, including gathering information, preparing, and submitting the completed form to the USPTO. Time will vary depending upon the individual case, Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chlef Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Mail Stop PCT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



PTO-1390 (Rev. 07-2005)
Approved for use through 3/31/2007. OMB 0651-0021
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

U.S. APPLICATION	15809	, see 33 CFR 1.5)	INTERNATIONAL A PCT/BE2004/0		ATTORNEY'S DO 29248/2	
20. Other items or information: International Search Report (9 pgs) International Preliminary Report on Patentability (14 pgs						
The foll	owing fees have b	een submitted			CALCULATIONS	PTO USE ONLY
21. 🗹 Basi				\$ 300.00		
22. Examination fee (37 CFR 1.492(c)) If the written opinion prepared by ISA/US or the international preliminary examination report prepared by IPEA/US indicates all claims satisfy provisions of PCT Article 33(1)-(4)\$0 All other situations					\$ 200.00	
23. Search fee (37 CFR 1.492(b)) If the written opinion of the ISA/US or the International preliminary examination report prepared by IPEA/US indicates all claims satisfy provisions of PCT Article 33(1)-(4)				\$ 400.00		
	TOTAL OF 21, 22	2 and 23 =			\$ 900.00	
Additional fee for specification and drawings filed in paper over 100 sheets (excluding sequence listing in compliance with 37 CFR 1.821(c) or (e) or computer program listing in an electronic medium) (37 CFR 1.492(j)). The fee is \$250 for each additional 50 sheets of paper or fraction thereof. Total Sheets Extra Sheets Number of each additional 50 or fraction thereof (round up to a whole number)				-		
253 - 100 =	153 /50 =	4 x \$250		\$ 1000.00	ı	
Surcharge of \$130.00 for furnishing any of the search fee, examination fee, or the oath or declaration after the date of commencement of the national stage (37 CFR 1.492(h)).				\$		
7 CLAIMS	NUMB	ER FILED NUMBER EXTRA RATE		\$		
Total claims		28 - 20 =	8	x \$50	\$ 400.00	<u> </u>
Independent clair	ms	4 -3=	1	x \$200	\$ 200.00	
MULTIPLE DEPENDENT CLAIM(S) (if applicable) + \$360			\$			
TOTAL OF ABOVE CALCULATIONS =			\$ 2500.00			
Applicant claims small entity status. See 37 CFR 1.27. Fees above are reduced by ½.						
SUBTOTAL =				\$ 1250.00		
Processing fee of \$130.00 for furnishing the English translation later than 30 months from the earliest claimed priority date (37 CFR 1.492(i)).			\$			
TOTAL NATIONAL FEE =			\$ 1250.00			
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property +			\$			
TOTAL FEES ENCLOSED =				\$ 1250.00		
		· ·			Amount to be refunded:	\$
					Amount to be charged	\$

AP20 Rec'd PCI/PT0 31 MAY 2006,

Approved for use through 3/31/2007. OMB 0651-0021

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

a. 🗹 A check i	n the amount of \$ 1,250.00	to cover the above for	ees is enclosed.				
	narge my Deposit Account No te copy of this sheet is enclosed.	in the amount of \$	to cover the above fees.				
	The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. <u>01-1785</u> . A duplicate copy of this sheet is enclosed.						
	Fees are to be charged to a credit card. WARNING : Information on this form may become public. Credit card information should not be included on this form . Provide credit card information and authorization on PTO-2038.						
NOTE: Where an appropriate time limit under 37 CFR 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the International Application to pending status.							
SEND ALL CORRE	SPONDENCE TO: n & Ebenstein LLP	- -	SIGNATURE Alan D. Miller NAME 42,889 REGISTRATION NUMBER				

Intellectual Property Law

90 Park Avenue New York NY 10016

Main 212 336 8000 212 336 8001 Web www.arelaw.com

Morton Amster lesse Rothstein (1934 - 2003) Daniel Ebenstein Philip H. Gonfried Michael J. Berger Neil M. Zipkin Anthony F. Lo Cicero Kenneth P. George Abraham Kasdan, Ph.D. Ira E. Silfin Chester Rothstein Craig J. Arnold Kenneth M. Bernstein

Joseph M. Casino

Senior Counsel Charles R. Macedo

Michael V Sola

Associates Patrick Boland John S. Economou Holly Pekowsky Michael P. Kenney Marion P. Metelski Max Vern Karl J. Kolbinger

Brian A. Comack Richard S. Mandaro

David Mimick

Charles W. Rath

David A. Boag

Jung S. Hahm

John A. Lepore

Reiko Kaji

Matthieu Hausig

Alan D. Miller, Ph.D.

Norajean McCaffrey

3/58076

Benjamin M. Halpern* Matthew A. Fox

*Not admitted in New York

May 31, 2006

Via Express Mail (EL 993158309 US)

Mail Stop PCT Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450 Alan D. Miller Direct 212 336 8094 E-mail amiller@arelaw.com

"Express Mail" mailing label no. EL 993158309 US Date of Deposit: May 31, 2006 I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail" service under 37 CFR 1.10 on the date indicated above and is addressed to the Commissioner for Patents, P.Q. Box 1450, Alexandria, VA 22313-1450. Name:

Re: United States National Stage Filing

of PCT Application No. PCT/BE2004/000172

Title: USE OF D4 AND 5-HT2A ANTAGONISTS, INVERSE AGONISTS

OR PARTIAL AGONISTS

Applicant: Erik Buntinx Our File: 29248/29

Dear Sir:

Pursuant to 35 U.S.C. § 371 and 37 C.F.R. § 1.495, enclosed please find an application for patent in the name of Erik Buntinx, entitled "USE OF D4 AND 5-HT2A ANTAGONISTS, INVERSE AGONISTS OR PARTIAL AGONISTS," for entering the national stage in the United States of America, comprising the following:

- a Transmittal Letter to the United States Designated/Elected 1. Office (DO/EO/US) Concerning a Filing Under 35 U.S.C. § 371 (3 pages);
- 2. a copy of PCT Application No. PCT/BE2004/000172 as published under PCT Publication No. WO 2005/053796A1, including cover page (1 sheet), specification (211 pages), claims (27 pages), figures (15 sheets), and International Search Report (9 pages);
- Preliminary Amendment and Information Disclosure Statement 3. (10 pages), Forms PTO/SB/08A-B (5 pages), and 40 references;

JAPZURECC PUTIFTO 31 MAY 2006

Commissioner for Patents

-2-

May 31, 2006

- 4. a copy of the International Preliminary Report on Patentability (14 pages) issued in connection with International Application PCT/BE2004/000172;
- 5. Declaration (3 pages) and Power of Attorney (1 page);
- 6. a check in the amount of \$1,250.00; and
- 7. a Return Receipt Postcard.

Please charge any outstanding amount or credit any overpayment to Deposit Account No. 01-1785. A duplicate copy of this letter is enclosed. Please also acknowledge receipt of the enclosed documents by stamping the enclosed postcard and returning the same to us.

Respectfully submitted,

AMSTER, ROTHSTEIN & EBENSTEIN LLP Attorneys for Applicant 90 Park Avenue New York, New York 10016

(212) 336-8000

Dated: New York, New York

May 31, 2006

By: Alan D. Miller

Registration No. 42,889